Clinical Trial Results: Hepatitis B, Chronic

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/1/2004
Phase: III
A Phase III Partially Double-Blind Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS) Combined With Placebo or Lamivudine Versus Lamivudine in HBeAg-Negative Patients With Chronic Hepatitis B (CHB)

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 6/1/2004
Phase: III
A Phase III Partially Double-Blinded Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS) Combined With Placebo or Lamivudine Versus Lamivudine in HBeAg-Positive Patients With Chronic Hepatitis B

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A multicenter, randomized, open label study comparing the efficacy and safety of 48 weeks of 40KD pegylated interferon alfa-2a (PEGASYS) versus 72 weeks of PEGASYS in naïve patients with HBeAg-negative chronic hepatitis

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection—Immunology Sub-Study of ML18253

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of Pegylated Interferon Alfa-2a (PEGASYS) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic hepatitis B (CHB)

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of Peginterferon Alfa-2a (PEGASYS) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 4/3/2006
Phase: IV
Efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS) in patients with HBeAg positive chronic hepatitis B.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 2/2/2007
Phase: III
A pilot study assessing efficacy and safety of peginterferon alfa-2a (PEGASYS) versus continuation of lamivudine (LAM) and/or adefovir dipivoxil (ADV) in patients with chronic hepatitis B pre-treated with LAM and/or ADV for >6 months. An open label, multi-center, randomized, national study.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: IV
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B.